Immunotherapy Safety for the Primary Care ... - U.S. Coast Guard

More documents

Recommendations

Info

Immunotherapy Contraindications •Who? – Conditions posing reaction survivability risk • Lung disease with FEV 1
Frequency of Systemic Reactions • 0.8% to 46.7% (mean 12.92%) systemic reaction rate for conventional AIT schedule. Stewart GE and Lockey RF J Allergy Clin Immunol 1992; 90: 567-78 • 45% of reactions occur in patients who have had previous systemic reactions. Matloff SM et al Allergy Proceed 1993; 14: 347-350
Page 1 and 2: Immunotherapy Safety for the Primar
Page 3 and 4: Welcome to “Immunotherapy Safety
Page 5 and 6: Click the ⌧ next to the topic to
Page 7 and 8: Immunotherapy at Remote Sites Stand
Page 9 and 10: What Immunotherapy Is Not • Not p
Page 11 and 12: How Does Immunotherapy Work? • De
Page 13 and 14: Who Benefits? •Those with… - Al
Page 15 and 16: Immunotherapy Efficacy • Effectiv
Page 17 and 18: Not Efficacious For… • Atopic d
Page 19 and 20: The Extracts/Vaccines • Bioequiva
Page 21 and 22: Lots of Numbers! Vial v/v W/V (exam
Page 23 and 24: Immunotherapy Phases • Maintenanc
Page 25 and 26: Reaction Prevention - Avoidance •
Page 27 and 28: Reaction Therapy - BLS+ Level • T
Page 29: Treatment Guidelines • Treatment
Page 33 and 34: Immunotherapy Safety • To lessen
Page 35 and 36: Immunotherapy Safety • To lessen
Page 37 and 38: Immunotherapy Safety • After Inje
Page 39 and 40: Immunotherapy Safety • Equipment:
Page 41 and 42: What To Expect (Demand) from the Al
Page 43 and 44: Summary • Risk factors for advers
Page 45: End of Selection Go to Bookmarks &
Page 48 and 49: • Allergen immunotherapy (allergy
Page 50 and 51: BEFORE EACH SHOT!!! • Screen pati
Page 52 and 53: instruct patient to report any abno
Page 54 and 55: • Negative (swelling up to 15mm;
Page 56 and 57: Epi-Pen Adult Epi-Pen JR TwinJect
Page 58 and 59: How to dilute from available vials:
Page 60 and 61: Vial v/v W/V AU/ML BAU/ML 5 Red 4 G
Page 62 and 63: Summary • Pull the patient's alle
Page 64 and 65: End of Selection Go to Bookmarks &
Page 66 and 67: a. Medical conditions that reduce t
Page 68 and 69: Allergen immunotherapy should be gi
Page 70 and 71: patient’s peak expiratory flow ra
Page 72 and 73: 7. Neilson L, Johnsen C, Mosbech H,
Page 74 and 75: Click the ⌧ next to the heading t
Page 76 and 77: a common practice to alternate the
Page 78 and 79: ALLERGY IMMUNOTHERAPY (AIT) PROBLEM
Page 80 and 81:
End of Selection Go to Bookmarks &
Page 82 and 83:
10. Those patients having their dos
Page 84 and 85:
SPECIFIC INSTRUCTIONS A. PHYSICIAN
Page 86 and 87:
ALLERGY IMMUNOTHERAPY RECORD NNMC,
Page 88 and 89:
Immunotherapy Pre-Injection Questio
Page 90 and 91:
Aeroallergen Dose Adjustment Schedu
Page 92 and 93:
NATIONAL NAVAL MEDICAL CENTER: Alle
Page 94 and 95:
ONGOING COMPETENCY ASSESSMENT OF UN
Page 96 and 97:
Page 98 and 99:
eflecting current robust documentat
Page 100 and 101:
Allergen immunotherapy: A practice
Page 102 and 103:
J ALLERGY CLIN IMMUNOL VOLUME 120,
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Immunotherapy Safety for the Primar
Page 164 and 165:
15. A 12 yo male presents for his a
Page 166 and 167:
Immunotherapy Safety for the Primar
Page 168 and 169:
Site Under Construction
Page 170 and 171:
Introduction • “Anaphylaxis”
Page 172 and 173:
Revised Nomenclature For Anaphylaxi
Page 174 and 175:
Anaphylaxis* Is Not Rare Estimated
Page 176 and 177:
Pathophysiology
Page 178 and 179:
Pathophysiology
Page 180 and 181:
Pathophysiology • Histamine acts
Page 182 and 183:
IgE Mediated Reactions • Most Ant
Page 184 and 185:
Complement-mediated • C5a, C3a, C
Page 186 and 187:
Unknown Mechanisms • Exercise-ind
Page 188 and 189:
Anaphylaxis Summary of Signs & Symp
Page 190 and 191:
Differential Diagnosis • Pulmonar
Page 192 and 193:
Anaphylaxis Grading Scale II • An
Page 194 and 195:
Laboratory Studies • IgE antibodi
Page 196 and 197:
Guidelines for Treatment • Treatm
Page 198 and 199:
Guidelines for Treatment • Treatm
Page 200 and 201:
How the Allergist/Immunologist Can
Page 202 and 203:
Summary • Anaphylaxis: release of
Page 204 and 205:
ANAPHYLAXIS • First reported case
Page 206 and 207:
4) Hymenoptera stings Although almo
Page 208 and 209:
• Sulfites are added to all the b
Page 210 and 211:
mastocytosis on bone marrow biopsy.
Page 212 and 213:
Antihistamines H1 antihistamines (B
Page 214:
Page 224 and 225:
The diagnosis and management of ana
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 267 and 268:
Page 269 and 270:
c. The patient will be counseled co
Page 271 and 272:
Page 273 and 274:
skin testing typically is performed
Page 275 and 276:
TABLE 3 Required Information on Vac
Page 277 and 278:
TABLE 6 Checklist for Safe Vaccine
Page 279 and 280:
Strength of Recommendations Key cli
Page 281 and 282:
Original articles Evaluation of nea
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Allergy Treatment Record Review Cha
Page 291 and 292:
References Acknowledgment: Linda Co
show all

Immunotherapy Safety for the Primary Care ... - U.S. Coast Guard

Create successful ePaper yourself

Delete template?

Save as template?